Daclizumab

DB00111ApprovedInvestigationalWithdrawnProtein Based TherapiesImmunomodulatory AgentsImmunosuppressive AgentsInterleukin-2 Receptor Blocking Antibody

Daclizumab is a monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis. Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25).

Protein structure of Daclizumab
Mechanism
Curator reviewed
Primary indication
Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejectionCurator reviewed · 1 structured indication
Formula / weight
C6332H9808N1678O1989S42 · 142612.1 Da
First approval
Canada, 2000 · United States, 1997
Also known as
Dacliximab · Daclizumab beta
Code names
RO 24-7375

Resolves to

Compound
UNIICUJ2MVI71YCAS152923-56-3ChEMBLCHEMBL1201605KEGGD03639
Clinical / RWD
RxNorm190353ATCL04AC01PharmGKBPA164764446
Targets
P01589IL2RAP14784IL2RBO75015FCGR3BP00736C1RP02745C1QAP02746C1QBP02747C1QCP08637FCGR3A+4 more

What you can answer from here — as of September 29, 2026

12Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
687Drug interactionsStructured to mechanism, not free text
Sign in
64Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
4ContraindicationsEach with its own population and attribute set
Sign in
14Marketed productsAcross 4 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 20 drug categories
Sign in
38+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Daclizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In